Featured Story

Vaxart's oral RSV candidate protects in preclinical challenge

While working to catch up with other vaccine developers in the race for a respiratory syncytial virus (RSV) vaccine, San Francisco-based Vaxart this week unveiled data demonstrating its candidate's ability to create a "substantial" immune response in a preclinical challenge model.

SUNY Upstate Medical University, U.S. Army start $12M partnership toward dengue vaccine

Sanofi is the furthest along in the race for a dengue vaccine, expecting its first license to market its jab by the end of the year. But this doesn't mean others aren't trying to tackle the mosquito-borne disease: SUNY Upstate Medical University announced on Monday a $12 million partnership with the U.S. Army to develop a dengue vaccine.

Daiichi Sankyo, Sanofi to launch DPT-polio vaccine in Japan

In the latest of a string a partnerships forged this year, Daiichi Sankyo is teaming up with Sanofi's Japanese unit to launch Squarekids subcutaneous injection syringe, a tetravalent vaccine for the prevention of diphtheria, pertussis, tetanus and polio.

BYU team devises method to speed up vaccine production

Brigham Young University researchers have developed a "just add water" method to expedite vaccine production in the face of new viruses. The process involves creating vaccine production machinery en masse and then freeze-drying it and stockpiling it in different locations.

GlaxoSmithKline Ebola vaccine shows safety in PhI

GlaxoSmithKline's experimental Ebola jab, which was taken to Phase I in the U.S. and Mali last October, was well-tolerated and elicited strong immune responses in adults.